EP3474842A4 - Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool - Google Patents

Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool Download PDF

Info

Publication number
EP3474842A4
EP3474842A4 EP17816377.0A EP17816377A EP3474842A4 EP 3474842 A4 EP3474842 A4 EP 3474842A4 EP 17816377 A EP17816377 A EP 17816377A EP 3474842 A4 EP3474842 A4 EP 3474842A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
devices
alcohol use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17816377.0A
Other languages
German (de)
English (en)
Other versions
EP3474842A1 (fr
Inventor
Roger CRYSTAL
Arvind Agrawal
Ed Maggio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior UK Ltd
Aegis Therapeutics LLC
Original Assignee
Aegis Therapeutics LLC
Opiant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegis Therapeutics LLC, Opiant Pharmaceuticals Inc filed Critical Aegis Therapeutics LLC
Publication of EP3474842A1 publication Critical patent/EP3474842A1/fr
Publication of EP3474842A4 publication Critical patent/EP3474842A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP17816377.0A 2016-06-24 2017-06-26 Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool Pending EP3474842A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354465P 2016-06-24 2016-06-24
US201662419736P 2016-11-09 2016-11-09
PCT/US2017/039300 WO2017223566A1 (fr) 2016-06-24 2017-06-26 Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool

Publications (2)

Publication Number Publication Date
EP3474842A1 EP3474842A1 (fr) 2019-05-01
EP3474842A4 true EP3474842A4 (fr) 2020-01-29

Family

ID=60784803

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17816377.0A Pending EP3474842A4 (fr) 2016-06-24 2017-06-26 Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool

Country Status (12)

Country Link
US (1) US20190209464A1 (fr)
EP (1) EP3474842A4 (fr)
JP (2) JP2019520361A (fr)
KR (2) KR102634829B1 (fr)
CN (1) CN109789122A (fr)
AU (2) AU2017281941A1 (fr)
CA (1) CA3028731A1 (fr)
MX (2) MX2018015985A (fr)
PH (1) PH12018502738A1 (fr)
RU (2) RU2767062C2 (fr)
SG (2) SG10202013034QA (fr)
WO (1) WO2017223566A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3474842A4 (fr) * 2016-06-24 2020-01-29 Opiant Pharmaceuticals, Inc. Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool
US20190262263A1 (en) * 2016-11-09 2019-08-29 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions
JP7312698B2 (ja) * 2016-11-18 2023-07-21 オーピアント ファーマシューティカルズ， インコーポレイテッド オピオイド過剰摂取を処置するための組成物および方法
US20210220346A1 (en) * 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
CN113573696A (zh) * 2018-12-20 2021-10-29 爱奇司治疗公司 用于治疗过剂量和奖赏系障碍的组合物、装置和方法
AU2020273810A1 (en) * 2019-05-16 2021-11-18 Shin Nippon Biomedical Laboratories, Ltd. Powder formulation for intranasal administration, and manufacturing method thereof
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023147443A2 (fr) * 2022-01-26 2023-08-03 Tulex Pharmaceuticals Inc. Nouvelles compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057934A1 (en) * 2012-08-22 2014-02-27 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140107145A1 (en) * 2004-08-25 2014-04-17 Aegis Therapeutics, Inc. Compositions for drug administration
US20140249172A1 (en) * 2012-12-13 2014-09-04 3B Pharmaceuticals, Inc. Intranasal naltrexone
US20150258287A1 (en) * 2013-08-22 2015-09-17 Sipnose Ltd Device to deliver a predetermined amount of a substance to a natural orifice of the body

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5069895A (en) * 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
IL97075A0 (en) * 1990-02-14 1992-03-29 Alcon Lab Inc Topical pharmaceutical composition containing an alkyl saccharide
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
CA2677205A1 (fr) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone pour le traitement de troubles addictifs
CA2697990A1 (fr) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Combinaisons de medicaments pour le traitement de l'alcoolisme et de la pharmacodependance
KR20100134078A (ko) * 2008-04-16 2010-12-22 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 트롬빈 고정화 생체 흡수성 시트 제제의 제조방법
CU24142B1 (es) * 2010-10-29 2015-12-23 Troikaa Pharmaceuticals Ltd Composiciones nasales de vitamina b12
KR101698182B1 (ko) * 2011-05-13 2017-01-19 유로-셀티큐 에스.에이. 날록손을 포함하는 비강내 제약 투여 형태
EP3082817A4 (fr) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions pour administration de médicaments
US9480644B2 (en) * 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
EP3474842A4 (fr) * 2016-06-24 2020-01-29 Opiant Pharmaceuticals, Inc. Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140107145A1 (en) * 2004-08-25 2014-04-17 Aegis Therapeutics, Inc. Compositions for drug administration
US20140057934A1 (en) * 2012-08-22 2014-02-27 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140249172A1 (en) * 2012-12-13 2014-09-04 3B Pharmaceuticals, Inc. Intranasal naltrexone
US20150258287A1 (en) * 2013-08-22 2015-09-17 Sipnose Ltd Device to deliver a predetermined amount of a substance to a natural orifice of the body

Also Published As

Publication number Publication date
RU2019101810A (ru) 2020-07-27
KR20220167279A (ko) 2022-12-20
CA3028731A1 (fr) 2017-12-28
RU2767062C2 (ru) 2022-03-16
RU2022103366A (ru) 2022-03-01
KR102634829B1 (ko) 2024-02-07
JP2022088592A (ja) 2022-06-14
SG11201811580SA (en) 2019-01-30
EP3474842A1 (fr) 2019-05-01
SG10202013034QA (en) 2021-02-25
MX2022013671A (es) 2022-12-13
AU2023202420A1 (en) 2023-05-11
PH12018502738A1 (en) 2019-10-21
AU2017281941A1 (en) 2019-02-07
CN109789122A (zh) 2019-05-21
JP2019520361A (ja) 2019-07-18
WO2017223566A1 (fr) 2017-12-28
JP7492548B2 (ja) 2024-05-29
KR102453781B1 (ko) 2022-10-12
MX2018015985A (es) 2019-09-13
US20190209464A1 (en) 2019-07-11
KR20190055057A (ko) 2019-05-22
RU2019101810A3 (fr) 2020-10-14

Similar Documents

Publication Publication Date Title
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3463248A4 (fr) Dispositifs et procédés d'utilisation de dispositifs d'administration de médicament
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
EP3373906A4 (fr) Compositions et procédés destinés à une application sur la peau
EP3151797A4 (fr) Méthodes et dispositifs de traitement de la peau
EP3474842A4 (fr) Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool
EP3538189A4 (fr) Compositions, dispositifs et méthodes pour le traitement de conditions médiées par un récepteur des opioides
EP3408344A4 (fr) Procédés et compositions de traitement de puits
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
EP3558279A4 (fr) Compositions et méthode s pour le traitement d'une douleur chronique
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
EP3117827A4 (fr) Composition vaginale et son utilisation
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3130620A4 (fr) Composition de silicone, composition d'émulsion de silicone, et agent de traitement de fibres
EP3522873A4 (fr) Compositions et méthodes pour le traitement de la xérostomie
EP3185910A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3426671A4 (fr) Composés et compositions pour le traitement d'infections
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3310358A4 (fr) Compositions et procédés pour le traitement de troubles d'utilisation de substances, d'accoutumance, et de troubles psychiatriques
EP3452044A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3411367A4 (fr) Compositions et méthodes de traitement d'infections bactériennes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/30 20060101ALI20191220BHEP

Ipc: A61K 9/08 20060101AFI20191220BHEP

Ipc: A61K 31/395 20060101ALI20191220BHEP

Ipc: A61P 25/32 20060101ALI20191220BHEP

Ipc: A61K 47/36 20060101ALI20191220BHEP

Ipc: A61K 47/18 20170101ALI20191220BHEP

Ipc: A61M 11/00 20060101ALI20191220BHEP

Ipc: A61P 25/00 20060101ALI20191220BHEP

Ipc: A61K 31/33 20060101ALI20191220BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004827

Country of ref document: HK

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OPIANT PHARMACEUTICALS, INC.

Owner name: AEGIS THERAPEUTICS, LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AEGIS THERAPEUTICS, LLC

Owner name: INDIVIOR UK LIMITED